As the NRG1-HER3 axis contributes to resistance to HER2-targeted therapy47, blocking the Notch pathway and the subsequent NRG1 downregulation might account for the beneficial effect of lapatinib-DAPT combination treatment on hyperglycemia-driven drug resistance. The gene discussed is ERBB3; the disease is Hyperglycemia.